115 related articles for article (PubMed ID: 25222407)
1. Summaries for patients. Comparative effectiveness of generic and brand-name statins on patient outcomes.
Ann Intern Med; 2014 Sep; 161(6):I-30. PubMed ID: 25222407
[No Abstract] [Full Text] [Related]
2. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387
[TBL] [Abstract][Full Text] [Related]
3. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
O'Brien EC; McCoy LA; Thomas L; Peterson ED; Wang TY
Am Heart J; 2015 Jul; 170(1):55-61. PubMed ID: 26093864
[TBL] [Abstract][Full Text] [Related]
4. The impact of manufacturer coupon use in the statin market.
Daugherty JB; Maciejewski ML; Farley JF
J Manag Care Pharm; 2013; 19(9):765-72. PubMed ID: 24156645
[TBL] [Abstract][Full Text] [Related]
5. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
6. Better outcomes with generic statins.
Harv Heart Lett; 2014 Dec; 25(4):8. PubMed ID: 26094262
[No Abstract] [Full Text] [Related]
7. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
8. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
9. Impact of formulary restrictions on medication use and costs.
Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of compliance and cost effectiveness between brand-name statins and generic statins].
He L; Du X; Wang WH; Ma CS
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Nov; 41(11):1900-1904. PubMed ID: 33297658
[No Abstract] [Full Text] [Related]
11. Zero copayment for generic statins could save billions.
Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806
[No Abstract] [Full Text] [Related]
12. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
13. When choosing statin therapy: the case for generics.
Green JB; Ross JS; Jackevicius CA; Shah ND; Krumholz HM
JAMA Intern Med; 2013 Feb; 173(3):229-32. PubMed ID: 23303273
[TBL] [Abstract][Full Text] [Related]
14. Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin.
Warraich HJ; Salami JA; Khera R; Valero-Elizondo J; Okunrintemi V; Nasir K
JAMA Intern Med; 2018 May; 178(5):719-721. PubMed ID: 29525818
[TBL] [Abstract][Full Text] [Related]
15. The paradigm of stains: will the lower cost of generics translate into health gains?
Seabra-Gomes R
Rev Port Cardiol; 2007 May; 26(5):497-501. PubMed ID: 17691276
[No Abstract] [Full Text] [Related]
16. Free statins disrupt pharmacy benefit plans.
Reinke T
Manag Care; 2012 Nov; 21(11):19-20. PubMed ID: 23236713
[No Abstract] [Full Text] [Related]
17. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
18. Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.
Li P; Schwartz JS; Doshi JA
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27836822
[TBL] [Abstract][Full Text] [Related]
19. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments.
Cicero AF; Derosa G; Parini A; Baronio C; Borghi C
Atherosclerosis; 2014 Jul; 235(1):81-3. PubMed ID: 24819746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
